A quiet crisis is unraveling the promise of modern obesity and cardiometabolic care—not due to drug inefficacy, but due to poor adherence. Despite breakthrough therapies like GLP-1s and SGLT2s, real-world persistence remains alarmingly low, with up to 70% of patients discontinuing by year three.
Dr. Pankaj Rajvanshi challenges the system-wide failure: what if adherence was part of the disease—not a patient flaw? By embedding behavioral support, digital nudges, simplified regimens, and real-time tracking into care design, we could transform outcomes.
Adherence benefits everyone: patients stay healthier, providers hit value-based metrics, payers cut costs, and pharma sees sustained use. So, who should fund the fix? Everyone. Because maybe it’s time we stop blaming patients—and start building care they can stick with.